Company Overview of AnaptysBio, Inc.
AnaptysBio, Inc., an antibody development company, engages in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology in the Unites states. It is developing ANB020, a pro-inflammatory cytokine antibody that inhibits the activity of interleukin-33; and ANB019, an antibody that inhibits the function of the interleukin-36-receptor. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is based in San Diego, California.
10421 Pacific Center Court
San Diego, CA 92121
Founded in 2005
Key Executives for AnaptysBio, Inc.
Chief Executive Officer, President and Director
Head of Project Management
Chief Development Officer
Compensation as of Fiscal Year 2015.
AnaptysBio, Inc. Key Developments
AnaptysBio, Inc. Announces First-In-Human Dosing of Anti-IL-33 Antibody
Mar 10 16
AnaptysBio, Inc. announced first-in-human dosing of its proprietary anti-IL-33 antibody (ANB020) in a Phase I clinical trial. The double-blind, placebo-controlled single and multiple ascending dose trial is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ANB020 in healthy volunteers. Interleukin-33, or IL-33, is a pro-inflammatory cytokine that multiple studies have indicated is a central mediator of atopic diseases, including atopic dermatitis, food allergies and asthma. IL-33 acts on white blood cell types that subsequently release atopic disease-mediating cytokines such as IL-5, IL-13 and IL-4. Since ANB020 potently inhibits IL-33 function, and acts upstream broadly across the key cell types involved in atopy, AnaptysBio believes its mechanism has potential advantages in human therapy over agents that block only a subset of the cytokines responsible for atopic diseases. The role of IL-33 signaling in asthma has been genetically validated through human studies published in the medical literature. Subsequent to the completion of this Phase I study, AnaptysBio plans to continue clinical development of ANB020 in patients with atopic dermatitis, peanut allergy and asthma.
AnaptysBio, Inc. Presents at Boston Biotech East West CEO Conference, Jan-10-2016 09:30 AM
Jan 1 16
AnaptysBio, Inc. Presents at Boston Biotech East West CEO Conference, Jan-10-2016 09:30 AM. Venue: Four Seasons Hotel, 757 Market St., San Francisco, CA 94103, United States. Speakers: Hamza Suria, Chief Executive Officer, President and Director.
AnaptysBio, Inc. Announces Appointment of James A. Schoeneck to Board of Directors
Nov 19 15
AnaptysBio, Inc. announced the appointment of James A. Schoeneck to its Board of Directors. Mr. Schoeneck is currently President & CEO of Depomed.
Similar Private Companies By Industry
Recent Private Companies Transactions
July 13, 2015